GSK and CureVac Restructure Partnership, Focusing on MRNA Vaccine Development

GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and

Benzinga7minutes ago

Sanofi's blockbuster drug Dupixent has been approved in Europe to treat pulmonary diseases.

Zhītōng Cáijīng APP learned that sanofi (SNY.US) heavyweight drug Dupixent has been approved for use in European patients with chronic lung disease, opening up a new path of growth. According to a statement from the company on Wednesday, European regulators became the first in the world to approve the vaccine as an additional treatment for patients with chronic obstructive pulmonary disease (some with high levels of white blood cells). In two milestone studies, the drug reduced disease progression, improved lung function, and improved quality of life. The decision makes Dupixent a treatment option for approximately 220,000 adult CO patients in the European Union.

Zhitong Finance7minutes ago

Express News | GlaxoSmithKline and curevac have redrafted their mRNA vaccine collaboration agreement

Breakings17minutes ago

GSK, CureVac Expand Licensing Agreement

By Anthony O. Goriainoff GSK said that under a new licensing deal with biotech company CureVac it will acquire full rights to develop, manufacture and commercialize internationally messenger RNA, or

Dow Jones26minutes ago

Express News | GlaxoSmithKline will pay 400 million euros to Curevac, a German biopharmaceutical company, and may pay up to 1.05 billion euros in the future. The two companies will carry out a reorganization cooperation.

Breakings45minutes ago

GSK Is Maintained at Buy by Jefferies

GSK Is Maintained at Buy by Jefferies

Dow Jones02:09